Covid Vaccine Race

The company will provide the vaccine group with 34 million doses in the fourth quarter of this year, and up to 466 million more doses in 2022.

A report said the vaccine may receive a US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the 12-15 year old population as early as next week.

Antibody levels induced by mRNA COVID-19 vaccines are much higher than those induced by natural infection and confer cross-reactivity that could be effective against new variants, a new study from the University of California, Irvine, found.

A treatment arm of up to 3000 participants aged 12-17 years old will be rolled into the North American-based PREVENT-19 trial.

The report details what symptoms vaccinated people should look out for, as well as treatment details for healthcare professionals.

With its mRNA COVID-19 vaccine authorized, the company is employing the technology to take aim at a variety of pathogens.

A pair of recent studies suggest that the ability of people with blood cancers lymphocytic leukemia and multiple myeloma to produce antibodies in response to COVID-19 vaccines is impaired.

Surveys suggest most students plan to get the shots anyway.

The Biden Administration plans to donate the AstraZeneca vaccines globally upon clearance of safety reviews.

Thailand steps up travel restrictions among a rapidly spreading third wave of the disease.

Nursing home residents who had recovered from COVID-19 showed robust antibody levels against the SARS-CoV-2 spike protein after 1 dose of messenger RNA (mRNA) vaccine, a study in France showed.

The Advisory Committee on Immunization Practices voted 10-4 with 1 abstention to resume the rollout and administration of the Janssen shot.

Providing support to communities of color could encourage participation and improve uptake.

New analysis of registry data suggest pregnant persons are not facing particularly worse pregnancy nor neonatal outcomes after mRNA vaccination.

Two cases in the United States showed reinfection after administration of the m-RNA vaccines may complicate protection against new variants, but lend support to a potential need for a booster.

The Johnson & Johnson shot showed an efficacy of 66.9% and 66.1% on the 2 primary endpoints, with a higher efficacy against severe-critical disease.

Federal regulators authored a 12 page report citing several examples of misconduct within the plant, including improperly trained employees.

Severe blood clots reported with 2 COVID-19 vaccines are rare, but possible heightening of vaccine hesitancy would lower floodgates to pandemic waves

The committee stressed that the events are exceedingly rare, and that the vaccine's benefits outweigh the potential risks.

A cardiology expert discusses the unique and currently investigated relationship between COVID-19, adenovirus vaccines, and thrombotic events.

Pathologic antibodies to platelet factor 4 in patients who developed clots after the AstraZeneca vaccine indicates treatment include non-heparin anticoagulant.

The 2 shot mRNA vaccine has a high efficacy against COVID-19, but long term data for its protection is not there yet, and emerging variants may present a challenge.

Increased facility-level vaccine coverage amongst residents and staff was associated with lower cases in the latter population.

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) met today to discuss the blood clots’ issue and offered guidance on heparin usage in these cases.

An interventional cardiologist discusses the observed cases of cerebral venous thrombosis in women administered the Johnson & Johnson COVID-19 vaccine.

Carlos del Rio, MD, discusses the United States' pandemic situation in assessing the blood clot events observed in 6 Johnson & Johnson vaccine recipients.

Jason Gallagher, PharmD, adds context behind the FDA and CDC's decision to pause and review blood clotting events in 6 women given the company's COVID-19 vaccine.

In a press conference this morning, leadership of the FDA and CDC discussed why they made the decision on this vaccine and announced an ACIP meeting will be held tomorrow to review the data from the adverse events.

The federal agencies will advise states withhold administration of the Johnson & Johnson one-shot product while investigating risk of a rare blood clot disorder.